-
Mashup Score: 0
Empagliflozin provided clinically relevant placebo-corrected reductions in HbA1c, whereas linagliptin did not, and might offer a new treatment option for young people with type 2 diabetes.
Categories: Endocrinology, Latest HeadlinesTweet
-
Mashup Score: 1
Empagliflozin provided clinically relevant placebo-corrected reductions in HbA1c, whereas linagliptin did not, and might offer a new treatment option for young people with type 2 diabetes.
Categories: Endocrinology, Latest HeadlinesTweet-
Online—Efficacy and safety of the #SGLT2 inhibitor #empagliflozin vs placebo and the #DPP-4 inhibitor #linagliptin versus placebo in young people with type 2 #diabetes (#DINAMO): a multicentre, randomised, double-blind, parallel group, phase 3 trial https://t.co/fdz3fO0EJm #T2D
-
-
Mashup Score: 0
Empagliflozin provided clinically relevant placebo-corrected reductions in HbA1c, whereas linagliptin did not, and might offer a new treatment option for young people with type 2 diabetes.
Categories: Endocrinology, Latest HeadlinesTweet-
New—Efficacy and safety of the #SGLT2 inhibitor #empagliflozin versus placebo and the #DPP-4 inhibitor #linagliptin versus placebo in young people with type 2 #diabetes (#DINAMO): a multicentre, randomised, double-blind, parallel group, phase 3 trial https://t.co/fdz3fO1cyU #T2D
-
-
Mashup Score: 0Empagliflozin restores neutropenia and neutrophil dysfunction in a young patient with severe congenital neutropenia type 4 - 1 year(s) ago
Severe congenital neutropenia type 4 (SCN-4) is a rare primary immunodeficiency caused by loss-of-function mutations in the gene G6PC3, encoding the ubiquitously expressed glucose-6-phosphatase-β enzyme, which hydrolyses glucose-6-phosphate to glucose in the endoplasmic reticulum (ER).1 Although it is described as a multisystem autosomal-recessive disorder with a diverse spectrum of…
Categories: Allergy-Immunology, Latest HeadlinesTweet-
In Current Issue! #Empagliflozin restores #neutropenia and #neutrophil dysfunction in a young #patient with severe #congenital neutropenia type 4 https://t.co/RjbRGwKpth https://t.co/UIoSuAB6y0
-
-
Mashup Score: 2
Empagliflozin on top of guideline recommended therapy improved CV and renal outcomes in HF with reduced ejection fraction, regardless of whether the cause of HF was ischemic or not, researchers.The results of a post hoc analysis of EMPEROR-Reduced that evaluated the efficacy and safety of empagliflozin (Jardiance, Boehringer Ingelheim/Eli Lilly) for patients with HFrEF from an ischemic cause
Source: www.healio.comCategories: Cardiology News and Journals, Latest HeadlinesTweet-
#Empagliflozin on top of guideline recommended therapy improved CV and renal outcomes in #HFrEF, regardless of whether the cause of HF was ischemic or not @JAHA_AHA @ShahzebKhanMD @DukeHeartCenter #cardiotwitter https://t.co/DGIPE5WTyM
-
-
Mashup Score: 4ESC Cardio Talk - The ESC Podcast - 1 year(s) ago
Hear Peter Libby, Deepak Bhatt, Franz Messerli, Roxana Mehran, Tom Guzik, and many more discussing the latest science that can impact your practice.
Source: www.escardio.orgCategories: Cardiology News and Journals, Latest HeadlinesTweet-
New #ESCCardioTalk with Alain Cohen Solal, Paolo Colombo & @AlexMebazaa They discuss: Assessing and treating congestion in acute decompensated heart failure: are we seeing the light at the end of the tunnel? https://t.co/JVu7XiFzxW #EHJ #Empagliflozin #CVD #SGLT2 #heartfailure https://t.co/ZCKVSbzW6A
-
-
Mashup Score: 1
A phase 3 trial of empagliflozin demonstrated statistically significant HbA1c reduction among children and adolescents aged 10 to 17 years with type 2 diabetes, according to a press release from Eli Lilly.“With more than 41,000 new cases worldwide annually, type 2 diabetes in today’s young people is a global public health issue, especially in light of the rise of risk factors such as
Source: www.healio.comCategories: Endocrinology, Latest HeadlinesTweet-
Among children and adolescents aged 10 to 17 years with type 2 #diabetes, #empagliflozin led to statistically significant reductions in HbA1c compared with placebo. @LillyPad https://t.co/ckvM4BYsiK
-
-
Mashup Score: 11Empagliflozin in Black Versus White Patients with Heart Failure: Analysis of EMPEROR-Pooled - 2 year(s) ago
Nitish K. DhingraNitish K. Dhingra Division of Cardiac Surgery, St. Michael’s Hospital, University of Toronto, Toronto, Canada , Stefan D. AnkerStefan D. Anker https://orcid.org/0000-0002-0805-8683 Department of Cardiology (CVK) and Berlin Institute of Health Center for Regenerative Therapies, German Centre for Cardiovascular Research Partner Site Berlin, Charité Universitätsmedizin, Berlin,…
Source: CirculationCategories: Cardiology News and Journals, Latest HeadlinesTweet-
#OriginalResearch simpub #AHA2022 #CIRCAHA22: The efficacy and safety of #empagliflozin was similar in Black and White patients with HF across the range of EF, with a suggestion of enhanced efficacy in Black patient... @JavedButler1 @FaiezZANNAD @lamcardio https://t.co/c7LMA1O9yL https://t.co/8wihsizMAK
-
-
Mashup Score: 0
Background: Sodium-glucose co-transporter 2 (SGLT2) inhibitors have been demonstrated to promote reverse cardiac remodeling in people with diabetes or heart failure. While it has been theorized that
Source: CirculationCategories: Cardiologists, Latest HeadlinesTweet-
Empagliflozin and LV Remodeling in People Without DM : Primary Results of the EMPA-HEART 2 CardioLink-7 #SGLT2i with #empagliflozin did not result in any meaningful changes in LV structure or function as assessed by #WhyCMR at 6 months #AHA22 @CircAHA https://t.co/D694p1JAi7
-
-
Mashup Score: 2Dr Jennifer Green Discusses Positive Efficacy of Empagliflozin Among Patients With CKD in the EMPA-KIDNEY Trial - 2 year(s) ago
Jennifer Green, MD, professor of medicine at Duke University School of Medicine, member of Duke Clinical Research Institute, and EMPA-KIDNEY collaborator, discussed findings of the EMPA-KIDNEY trial presented at Kidney Week 2022, which showed a 28% improvement for patients with chronic kidney disease (CKD) on empagliflozin, whether in reduced mortality from cardiovascular disease or progression…
Source: AJMCCategories: General Medicine Journals and Societies, Latest HeadlinesTweet-
Tune in to our interview with Dr Jennifer Green as she discusses positive efficacy of #Empagliflozin among patients with #CKD in the #EMPAKIDNEY Trial. #KidneyWk https://t.co/chNYZseJQO https://t.co/ap6Kc5SyF4
-
Online—Efficacy & safety of the #SGLT2 inhibitor #empagliflozin vs placebo & the #DPP-4 inhibitor #linagliptin versus placebo in #young #people with type 2 #diabetes (#DINAMO): a multicentre, randomised, double-blind, parallel group, phase 3 trial https://t.co/fdz3fO0EJm #T2D